Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8735193 | 0.94 | SIGMAR1 (0.47) | SIGMAR1SMN1; SMN2CHRM2HTR1AADRA2A | |
| SCHEMBL11644544 | 0.92 | SIGMAR1 (0.49) | SIGMAR1KCNH2 | |
| SCHEMBL16915556 | 0.92 | SIGMAR1 (0.49) | SIGMAR1KCNH2 | |
| SCHEMBL27816692 | 0.91 | LMNA (0.44) | SIGMAR1SMN1; SMN2 | |
| SCHEMBL19090603 | 0.89 | SIGMAR1 (0.50) | SIGMAR1 | |
| SCHEMBL598729 | 0.87 | TSHR (0.47) | SMN1; SMN2 | |
| SCHEMBL9543267 | 0.86 | SIGMAR1 (0.50) | SIGMAR1CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL7362511 | 0.86 | KCNH2 (0.47) | SIGMAR1CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL10711841 | 0.85 | TSHR (0.46) | SMN1; SMN2 | |
| SCHEMBL9821375 | 0.85 | TSHR (0.46) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463374-A2 | Isolated alcohol dehydrogenase enzymes and uses thereof | Bio Architecture Lab, Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| EP-2195440-A2 | BIOFUEL PRODUCTION | Bio Architecture Lab, Inc. (US) | 2010-06-16 | — | — | EP | claimed |
| US-20090155873-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-18 | — | — | US | claimed |
| US-20090139134-A1 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-06-04 | — | — | US | claimed |
| WO-2009046375-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2009046370-A2 | BIOFUEL PRODUCTION | BIO ARCHITECTURE LAB, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| EP-3230463-B2 | RAPID PRETREATMENT | APALTA PATENTS OUE (EE) | 2025-07-16 | — | — | EP | disclosed |
| US-20240425893-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2024-12-26 | — | — | US | disclosed |
| US-12054761-B2 | Rapid pretreatment | Apalta Patents OÜ (EE) | 2024-08-06 | — | — | US | disclosed |
| US-11821047-B2 | High pressure zone formation for pretreatment | Apalta Patent OÜ (EE) | 2023-11-21 | — | — | US | disclosed |
| US-20230295678-A1 | RAPID PRETREATMENT | Apalta Patents OÜ (EE) | 2023-09-21 | — | — | US | disclosed |
| EP-4098750-A1 | RAPID PRETREATMENT | Sweetwater Energy, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3230463-B1 | RAPID PRETREATMENT | SWEETWATER ENERGY INC (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-0107492-B1 | HELICHROMIC-SMECTIC LIQUID CRYSTAL COMPOSITIONS AND DISPLAY CELLS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-08-09 | — | — | EP | disclosed |
| US-4526890-A | Respiratory system disorders | THE DOW CHEMICAL COMPANY (US) | 1985-07-02 | — | — | US | disclosed |
| EP-0044666-B1 | HELICHROMIC COMPOUNDS AND DISPLAYS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1985-05-29 | — | — | EP | disclosed |
| US-4514045-A | DICHROISM; COMPLETE LIGHT ABSORPTION; LOW VOLTAGE; CONTRAST | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1985-04-30 | — | — | US | disclosed |
| EP-0107492-A2 | Helichromic-smectic liquid crystal compositions and display cells | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1984-05-02 | — | — | EP | disclosed |
| US-4394070-A | Helichromic compounds and displays | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1983-07-19 | — | — | US | disclosed |
| EP-0044666-A2 | Helichromic compounds and displays | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1982-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090139134-A1 | BIOFUEL PRODUCTION | MGAM, DCXR, MANBA | SIGMAR1 4688/4885SMN1; SMN2 4593/4885CHRM2 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.